This month’s roundup of new hires, promotions and awards involves Gilead Sciences, Cardiff Oncology, Science 37, and other notable firms.
This month’s roundup of new hires, promotions and awards involves Gilead Sciences, Cardiff Oncology, Science 37, and other notable firms.
Gilead Sciences has tapped Mark Genovese to serve as senior vice president of inflammation. In his new role, Genovese will oversee the clinical development of the company’s investigational portfolio of treatments for inflammatory conditions.
Genovese had been on the faculty of Stanford University for more than 21 years, most recently as the James W. Raitt Professor of Medicine and Clinical Chief in the Division of Immunology and Rheumatology. At the university, he established a clinical research program focused on translational medicine in autoimmune diseases and led numerous investigator-initiated studies and international multi-center trials for the treatment of rheumatological diseases, including arthritis.
Clinical-stage oncology therapeutics company Cardiff Oncology (formerly Trovagene) has appointed Thomas Adams as executive chairman. He will transition from his role as chairman of the company.
Adams had served as chairman of the company’s board since 2009 and CEO since June 2018. In his new role, Adams will provide strategic guidance and drug development expertise to the company.
Clinical-stage oncology therapeutics company Cardiff Oncology (recently renamed from Trovagene) has named Mark Erlander to the position of CEO. He will transition from his role as chairman of the company.
Erlander, who had served as chief scientific officer since joining the firm in 2013, said, “I'm excited to lead our company into the next stage of development that includes continuing to rapidly advance development of our investigational drug, onvansertib, in cancers with the greatest medical need for new effective treatments."
Pharmaceutical firm Ipsen has appointed David Loew CEO and new board member, effective July 1. His mission will be to ensure the company’s growth and advance its products through innovation.
Loew had been CEO of Sanofi Pasteur Vaccines since 2016. He brings to the company nearly three decades across a range of therapeutic areas (including oncology, CNS and cardio-metabolism), as well as consumer healthcare. He has worked for a number of companies in the US, European and international markets, including Roche and Hewlett Packard.
Marc De Garidel, chairman of Ipsen, said, “I have full confidence that David will provide the leadership and expertise needed to guide the group through its next phase of growth and realize Ipsen’s vision of being a global biotechnology leader through the identification, development and commercialization of transformative and differentiated products.”
Virtual trial technology firm Science 37 has hired Mike Zaranek as CFO. In the role, he will oversee all aspects of finance, accounting, and strategic pricing as the company prepares for its next stage of growth.
Zaranek comes from IQVIA's Contract Sales and Medical Solutions division. There, he served as vice president of finance for the global business unit, which had 2019 revenues of more than $800 million.
“Mike has built a successful track record in his career by maximizing customer value and delivering transformational growth with strong financial strategies,” said David Coman, CEO of Science 37. “I’m confident that his business acumen, leadership, and experience will help Science 37 extend its market-leading position.”
Drug development and regulatory science specialists Cetrara has appointed Terrance Ocheltree as vice president of regulatory strategy and chemistry, manufacturing and controls.
In his new role, Ocheltree will provides technical and strategic advice on CMC activities to support product development, from pre-investigational new drug (IND) submission to commercialization and the establishment of supply chains. His past experience includes five years at AbbVie as senior director in regulatory, and eight years at the US Food and Drug Administration (FDA) in the office of new drug quality assessment as a reviewer and division director.
Life-sciences company Albumedix has appointed Jonas Skjødt Møller as its new CEO, effective July 1. With the company for eight years, Møller has held a number of positions within the company, including in the laboratories and on the front line with customers.
“The opportunities ahead are game changing, especially today as we witness the need globally for rapidly scalable vaccine platforms and advanced therapies to significantly transform lives,” Møller said. "The vision is to empower excellence: in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally.”
The German contract development and manufacturing award (CDMO) has landed the Axia Best Managed Companies Award. The honor recognizes medium-size companies with a demonstrated clear vision, innovative approaches, sustainable management culture and sound financial management.
“Our success story is based on long-term corporate planning and strategy over the decades,” said honorary senator Udo J. Vetter, chairman of the advisory board and member of the owner family. “This award goes to our employees.”
Laboratory technology manufacturer H.E.L Group has hired Mert Sahin general manager and senior vice president of North American operations. He had most recently served as chief marketing officer for GE Healthcare’s medical imaging business.
Louise Madden, CEO of H.E.L Group, said Sahin will focus on the needs of the company’s North American customers, helping them reach their goals.
“Despite these uncertain times, H.E.L recognizes the underlying strength of the North American market and the potential for significant growth,” she said. “Mert will help us to build and deploy a stronger team across North America, to take advantage of this growth potential.”